LONG-TERM INTRAVENOUS CALCITRIOL IN SECONDARY HYPERPARATHYROIDISM: THE ROLE OF TECHNETIUM-99M-MIBI SCINTIGRAPHY IN PREDICTING THE RESPONSE TO TREATMENT

Figures & data

Table 1. Characteristics of the Patients

	−ve MIBI Group (n = 7)	+ve MIBI Group (n = 9)	P
Cause of ESRF
Chronic interstitial nephritis	1	1
Unknown (small kidneys)	4	6
Diabetic nephropathy	1	1
ADPKD	1	1
Sex
Male	2	3
Female	5	6
Age (years) mean ± S.D.	45.4 ± 17.8	47.1 ± 5.3	0.791*
Duration of dialysis (months) mean ± S.D.	70 ± 27	68.7 ± 27.8	0.931*

*Statistically not significant.

Table 2. Reduction in iPTH

	−ve MIBI Group iPTH2^∞ Mean±S.D. (% Reduction)	+ve MIBI Group iPTH2^∞ Mean±S.D. (% Reduction)	p (of the Mean)	95% C.I.
0 Month	535±180	635±278	0.4243*	−360 to 160
12 Months	198±111 (65%)	303±150 (45%)	0.1463*	−250 to 41
24 Months	122±62 (77%)	330±149 (48%)	0.0034^†	−329 to −87
36 Months	170±47 (65%)	501±322 (10%)	0.0184^†	−596 to −65

^∞iPTH (pg/ml);

*Statistically not significant;

^†Statistically significant.

Table 3. Level of Serum Calcium (mmol/l)

	−ve MIBI Group (Mean ± S.D.)	+ve MIBI Group (Mean ± S.D.)	p
0 Month	2.11 ± 0.36	2.24 ± 0.17	0.3225*
12 Months	2.40 ± 0.11	2.57 ± 0.27	0.1355*
24 Months	2.52 ± 0.15	2.50 ± 0.23	0.8315*
36 Months	2.50 ± 0.23	2.57 ± 0.28	0.605*

*Statistically not significant.

Table 4. Level of Serum Phosphate (mmol/l)

	−ve MIBI Group (Mean ± S.D.)	+ve MIBI Group (Mean ± S.D.)	p
0 Month	1.96 ± 0.46	1.84 ± 0.57	0.6756*
12 Months	1.97 ± 0.31	1.83 ± 0.37	0.4756*
24 Months	1.94 ± 0.44	1.97 ± 0.51	0.9326*
36 Months	2.26 ± 0.41	1.93 ± 0.45	0.1596*

*Statistically not significant.

Table 5. Level of Alkaline Phosphatase (IU/l)

	−ve MIBI Group (Mean±S.D.)	+ve MIBI Group (Mean±S.D.)	p
0 Month	478±286	425±225	0.6817*
12 Months	208±103	188±47	0.6127*
24 Months	215±135	298±108	0.1927*
36 Months	236±203	250±80	0.8517*

*Statistically not significant.

Figure 1. Response to calcitriol in −ve scan patients.

Figure 2. Response to calcitriol in +ve scan patients.

Figure 3. Mean iPTH in the 2 groups.